Advanced PCOS Relief

AOR04366

Aide à normaliser la function ovarienne

  • Améliore le taux de glycémie et l’humeur
  • Favorise le bon fonctionnement des ovaires et améliore la qualité des ovules
  • Fournit la forme biologiquement active de l’acide folique pour favoriser les fonctions reproductrice, hormonale, cardiaque et cérébrale
  • Régularise le cycle menstruel et inverse certaines causes d’infertilité
Eco
Vegan Society
Sans Gluten
Sans OGM

$49.86

En stock

Soulagement Avancé SOPK est une formule complète qui offre une approche naturelle et sûre pour résoudre les symptômes et complications du SOPK tels que l’infertilité, les fluctuations du taux de glycémie, le gain de poids, un cycle menstruel irrégulier, une pilosité excessive et les perturbations de l’humeur. Les femmes ne souffrant pas spécifiquement du SOPK, mais présentant des problèmes hormonaux et du système reproducteur similaires peuvent également utiliser ce produit.

L’inositol est un nutriment semblable aux vitamines B que l’on retrouve dans bon nombre d’aliments, notamment les céréales et les agrumes. Au cours des dernières années, la recherche a pu établir l’action puissante de fortes doses de cet élément nutritif sur la régulation du cycle menstruel, le bon fonctionnement des ovaires, l’équilibre de l’humeur et la régulation de facteurs métaboliques. Le myo- et le D -chiro-inositol sont deux formes distinctes d’inositol. Tandis que le myo-inositol est la forme la plus abondante dans la nature, le d -chiro-inositol, lui, est fabriqué par le corps à partir du myo-inositol. Chacune de ces formes couvre différentes fonctions dans le corps; ce qui rend impératif le maintien d’un bon ratio de ces deux molécules. Des recherches récentes démontrent que l’association myo-inositol – D -chiro-inositol est plus efficace pour soutenir l’activité de l’insuline, la fonction ovarienne, le métabolisme, l’équilibre de l’humeur et des taux normaux d’androgènes.

Soulagement Avancé SOPK contient trois nutriments ayant démontré leur efficacité dans la gestion du SOPK; ce sont notamment le myo-inositol, le D -chiro-inositol et le 5 – MTHF qui est la forme biologiquement active de l’acide folique. L’enzyme de conversion de l’acide folique standard en 5 – MTHF afin que le corps puisse l’utiliser est généralement déficiente chez bon nombre de personnes.

ADVANTAGE AOR

Advanced PCOS Relief fournit à la fois du myo-inositol et du d-chiro-inositol dans des rapports étayés par la recherche clinique. Il comprend également la forme 5-MTHF d’acide folique pour assurer son efficacité.

NPN

80066991

DISCUSSION

Soulagement Avancé SOPK aide à normaliser la fonction ovarienne, l’ovulation, la qualité de l’ovocyte et les irrégularités du cycle menstruel chez les femmes souffrant du SOPK (syndrome des ovaires polykystiques). Il aide également à gérer les troubles hormonaux, métaboliques et la sensibilité à l’insuline. De plus, il aide à rétablir les taux de grossesse chez les femmes de moins de 36 ans atteintes de SOPK et qui suivent un programme de fécondation in vitro.

CERTIFIE

AOR™ certifie que tous les ingrédients sont mentionnés sur l’étiquette. Ne contient ni blé, ni gluten, ni noix, ni arachide, ni graine de sésame, ni moutarde, ni soja, ni produit laitier, ni œuf, ni poisson, ni mollusque ou crustacé.

POSOLOGIE ADULTE

Prendre 2 capsules deux à quatre fois par jour, avec ou sans nourriture, ou selon les recommandations d’un professionnel de la santé. Prendre ce produit pendant au moins 12 semaines afin de constater les effets bénéfiques. Eviter d’ouvrir les capsules ; cela pourrait compromettre la stabilité des ingrédients médicinaux.

MISES EN GARDE

Consulter un professionnel de la santé avant de prendre ce produit pour un traitement efficace et sûr en cas d’infertilité. Consulter un professionnel de la santé avant l’utilisation si vous êtes enceinte, si vous allaitez ou si vos symptômes persistent ou s’aggravent.

AVERTISSEMENT

Les renseignements sur les produits contenus dans ce site web, y compris la description des produits, leurs effets potentiels et leurs avantages sont destinés à des fins d’information uniquement. Ils ne sont pas destinés à donner ou remplacer les renseignements médicaux ou l’avis d’un professionnel qualifié. Consulter votre médecin pour tout problème de santé

Main Application
  • Polycystic Ovarian Syndrome
  • Infertility
  • Acne
  • Glucose management and regulation
  • Mood
  • Menstrual symptoms
Portion: Two Capsules
Acide folique (de L-5-MTHF de calcium)
200 mcg
myo-Inositol
275 mg
D-chiro-Inositol
6.9 mg

Ingrédients non-médicinaux : cellulose microcristalline et palmitate d’ascorbyle.

Capsule: hypromellose.

Poly Cystic Ovarian Syndrome (PCOS):Study 1:This randomized, placebo-controlled clinical study aimed to evaluate the effect of a combination of folic acid, myo-inositol (MI), and D-chiro inositol (DCI) in young overweight women with polycystic ovary syndrome (PCOS), characterized by anovulation and hyperandrogenism, correlated to insulin resistance. Participants received either a placebo or folic acid (200 μg) + MI (550 mg) + DCI (13.8 mg) twice daily for 6 months. At baseline, all patients did not differ significantly and were in the follicular phase of their menstrual cycle. All patients were evaluated for FSH, LH, 17-beta-Estradiol (E), Sex Hormone Binding Globulin (SHBG), androstenedione, free testosterone, and dehydroepiandrosterone sulphate (DHEAS) levels at the baseline and after the six months of therapy.The results show a statistically significant reduction of LH, free testosterone, fasting insulin, and HOMA index in the combination therapy group, compared to the placebo. Additionally, an increase in 17-beta-Estradiol levels was observed in this group, suggesting that the combination supplementation with MI, DCI, and folate is effective in improving endocrine and metabolic parameters in young overweight women affected by PCOS.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4963579/Study 2:This study describes the effect of inositols supplementation on the metabolic profile of women with a diagnosis of PCOS. This prospective, case-control clinical study enrolled 30 participants – 15 PCOS patients and15 control women and they were supplemented with Myo-inositol (1.75 g per day), D-chiro-inositol (0.25 g per day) and glucomannan, a water-soluble fiber from the konjac root (4 g per day) for three months. Blood concentrations of glucose, insulin, triglycerides, and cholesterol, and ovary volumes and antral follicles count, as well as metabolomic profiles, were evaluated for control subjects and PCOS patients before and after treatment.At baseline, the PCOS patients had a higher BMI than the control group. Following supplementation, the BMI in the PCOS women decreased significantly. This study also identified metabolites in the PCOS women that were specifically correlated with the diagnosis of PCOS and the therapeutic exposure to inositols. These results suggest that inositol supplementation can improve the metabolomic pathways and metabolic profiles in women with PCOS.https://ovarianresearch.biomedcentral.com/articles/10.1186/s13048-019-0500-xStudy 3:A systematic review and meta-analysis of clinical studies that evaluated the effect of inositol supplementation in women with PCOS were published in 2017. This publication reviewed randomized, controlled studies for the effect of inositols as ovulation induction agents.the meta-analysis included 10 randomized trials, with 362 women on inositol (257 on Myo-inositol and 105 on D-chiro-inositol), 179 women on placebo and 60 were on metformin. The results and analysis show that inositol supplementation was associated with significantly improved ovulation rate and increase the frequency of menstrual cycles, compared with placebo groups. One of the studies reviewed reported increased pregnancy rates in the participants on inositol, compared with placebo groups. The authors conclude that supplementation with inositols improves menstrual cycles, ovulation, and metabolic changes in polycystic ovary syndrome.https://obgyn.onlinelibrary.wiley.com/doi/full/10.1111/1471-0528.14754Study 4:Another systematic review evaluated clinical evidence for the effect of inositol supplementation on glucose and insulin sensitivity, 17β-estradiol (E2), testosterone (T), androstenedione (A), the homeostatic model assessment (HOMA) index, sex hormone-binding globulin (SHGB), r-FSH, stimulation days, oocyte quality, embryo quality, biochemical pregnancies, and pregnancy rate. This review draws attention to the importance of the ratio between Myo-inositol and D-chiro inositol supplementation in PCOS. Two of the studies reviewed suggest that deficiencies of these two inositols might be a contributing factor to the pathophysiology of insulin resistance in PCOS patients.The results conclude that inositol supplementation, particularly MI and DCI contribute to improving several of the hormonal and reproductive disturbances of PCOS; furthermore, the analysis lends prominence to the pivotal role of MI and DCI in enhancing oocyte follicular development and oocyte maturation, as well as in the stimulation and pregnancy outcomes in in-vitro fertilization (IVF) procedures.https://www.hindawi.com/journals/ije/2016/1849162/Study 5:As with the previous meta-analysis summary, the importance of the right dose and ratios of Myo-inositol and D-chiro-inositol is a determining factor in the effects observed with supplementation. In this randomized, placebo-controlled clinical study, PCOS patients were randomized into one of 5 groups: a placebo group, and four groups receiving increasing doses of D-chiro-inositol (300, 600, 1200 and 2400 mg) daily for eight weeks. Higher doses of DCI was associated with increased r-FSH and the number of immature oocytes, compared to the lower dose groups and placebo groups. The results suggest that increased DCI dosage is associated with the worsening of oocyte quality and ovarian response. Proper dosage of DCI is essential to the positive response in PCOS patients.https://ovarianresearch.biomedcentral.com/articles/10.1186/1757-2215-5-14Infertility:Study 1:The aim of this prospective, randomized, open-label, multicenter pilot study was to examine the effect of myo-inositol administration on ovarian response and oocytes and embryo quality in non-PCOS patients, undergoing multiple follicular stimulation and in-vitro insemination (IVS) by in-vitro fertilization (IVF). Patients were randomized to receive either folic acid or a combination of folic acid and Myo-inositol for three months prior to follicular stimulation by r-FSH (150 IU per day for 6 days). The results showed that the total amount of gonadotropins needed to reach follicular maturation was significantly lower in the myo-inositol supplemented group. Additionally, the number of oocytes retrieved was significantly lower in this group. The results suggest that supplementation with Myo-inositol and folic acid in non-PCOS patients may reduce the numbers of mature oocytes and dosage for follicular stimulation while maintaining pregnancy rates in non-PCOS patients undergoing stimulation for IVF.https://www.ncbi.nlm.nih.gov/pubmed/22823904Study 2:PCOS is usually associated with impaired glucose tolerance and a defect in the insulin-signaling pathway. These patients are also considered “sub-fertile” and usually require medication for ovulation induction. The aim of this study was to examine the effect of myo-inositol supplementation on the improvement of insulin-receptor activity and the restoration of normal ovulatory function. Twenty-five PCOS women of childbearing age with oligo- or amenorrhea were enrolled in the study. Ovulatory disorder due to PCOS was apparently the only cause of infertility. Participants were supplemented with 2 g twice daily of myo-inositol and folic acid for six months, during which time, ovulatory activity was monitored.The results suggest that Myo-inositol and folic acid supplementation was associated with restored spontaneous menstrual cycles, 72% of which maintained normal ovulatory activity. 40% of the patients got pregnant during the study. These results suggest that inositol and folic acid supplementation could help restore spontaneous ovarian activity and consequently fertility in PCOS patients.https://www.ncbi.nlm.nih.gov/pubmed/17952759Study 3:Myo-inositol (MI) and D-chiro-inositol (DCI), individually and in combination, are considered insulin-sensitizing agents, especially when given to patients with PCOS, suffering from infertility. The aim of this study was to compare the effects of MI and DCI on oocyte quality, as a marker of improved fertility in PCOS patients with normal glucose levels. All patients treated in the in vitro fertilization (IVF) Department of the researchers of infertility for a period of more than 12 months were asked to participate in the study. 43 patients received 2 g MI twice daily, while the other 43 patients received 0.6 g DCI twice a day for eight weeks before follicle-stimulating hormone (rFSH) administration.The results of this study showed no significant difference between both groups on the total number of oocytes retrieved, however, the number of mature oocytes, mean number of top-quality embryos, and total number of pregnancies was significantly higher in the group receiving myo-inositol.https://www.ncbi.nlm.nih.gov/pubmed/21608442Glucose Management/Metabolic Syndrome:Study 1:The aim of this study was to evaluate the effect of supplementation with myo-inositol on biochemical parameters of women affected by metabolic syndrome. Eighty post-menopausal patients were recruited for this 12-month study and randomly assigned to either a placebo group or Myo-inositol (2 g twice daily). All participants were assessed for serum glucose, insulin, HOMA-IR (Homeostasis Model Assessment-Insulin Resistance), triglycerides, total and high-density lipoprotein cholesterol, body mass index (BMI), waist circumference and blood pressure at baseline and after 12 months of treatment.The results show that supplementation with Myo-inositol was associated with significant improvement all but BMI and waist circumference parameters. Myo-inositol supplementation helped reduce the number of women with metabolic syndrome over the duration of the study.https://www.ncbi.nlm.nih.gov/pubmed/22192068Study 2:Gestational diabetes is associated with poor pregnancy outcomes and could have negative effects on both mother and child. The aim of this study was to evaluate the effect of myo-inositol supplementation on the onset of gestational diabetes in pregnant women with a familial history of type 2 diabetes. This prospective, randomized, open-label, placebo-controlled clinical study recruited 220 pregnant women, who were randomized to receive either a placebo and folic acid (200 μg) or myo-inositol (2 g) and folic acid (200 μg) twice a day, starting in the first trimester. The researchers assessed all participants for the following: the incidence of gestational diabetes and fetal macrosomia, gestational hypertension, pre-term delivery, cesarean section, shoulder dystocia, neonatal hypoglycemia, and neonatal distress respiratory syndrome.The results show a significantly reduced incidence of gestational diabetes, fetal macrosomia, and mean fetal weight in the myo-inositol supplemented group, compared to the placebo group.https://www.ncbi.nlm.nih.gov/pubmed/23340885A similar study, also published in 2013 showed similar effects of myo-inositol supplementation on reduction in the incidence of gestational diabetes and improved pregnancy outcomes https://www.ncbi.nlm.nih.gov/pubmed/23327487.A systematic review and meta-analysis of 4 randomized, controlled studies including 567 women confirmed the role of myo-inositol supplementation in reducing gestational diabetes incidence https://www.ncbi.nlm.nih.gov/pubmed/26678256.Study 3:In this randomized, controlled trial, researchers aimed to assess the effect of D-chiro-inositol and folic acid supplementation on glucose control and insulin resistance in overweight/obese patients with type I diabetes. Participants were randomized to receive either 400 μg folic acid daily (control) or a combination of folic acid (400 μg) and DCI (1000 mg) once daily and assessed for HbA1C, as a marker of blood sugar levels, as well as BMI and insulin requirement.DCI and folic acid supplementation led to a significant reduction in HbA1C levels, compared to the control group, suggesting that DCI and folic acid supplementation can improve metabolic control in overweight patients with type I diabetes.https://www.ncbi.nlm.nih.gov/pubmed/28039583Study 4:This prospective, randomized, placebo-controlled study aimed to evaluate the effect of myo-inositol supplementation in improving features of metabolic syndrome in postmenopausal women with metabolic syndrome. Participants were randomized to receive either a placebo or myo-inositol (2 g twice a day) for 6 months. Each group was also on a restricted diet for the duration of the study.The results indicate that myo-inositol supplementation improved systolic and diastolic blood pressure, HOMA index (as a measure of insulin resistance), cholesterol, and triglyceride serum levels, compared to the placebo group, providing sufficient evidence for the use of Myo-inositol supplementation in post-menopausal women with metabolic syndrome.https://www.ncbi.nlm.nih.gov/pubmed/20811299

Q: Are high doses of inositol safe?A: Inositol is extremely safe. Still, it is important to slowly and gradually increase the dose in some individuals in order to prevent the unwanted side effect of diarrhea. While this is a relatively rare concern, it is one that people tend to want to avoid.

Vous aimerez peut-être aussi…

Choix des options

Thé Vert Actif

Un antioxydant qui améliore la longévité

  • Puissant extrait de feuilles de thé vert; riche en EGCG
  • Favorise la perte de poids en stimulant le métabolisme
  • Effets puissants contre le vieillissement
  • Dose soutenue par la recherche
90-capsules-fr
180-capsules-fr